AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the meeting will close to the public and the following appraisal will be held in private

5. Appraisal 1: Full Submission (WPAS) Ivacaftor (Kalydeco®) for the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CFTR gene

The meeting will now re-open to the public

6. Chairman’s report (verbal update)


8. All Wales Multidisciplinary Medicines Reconciliation Policy

9. Appraisal 2: Full Submission Aviptadil phentolamine (Invicorp®) for symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasulogenic, psychogenic, or mixed aetiology

10. Date of next meeting – 19th July 2017 in Cardiff